Cognition Therapeutics, Inc. Accumulated Other Comprehensive Income
Cognition Therapeutics, Inc. (CGTX) had Accumulated Other Comprehensive Income of -$195.00 thousand as of 2023-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2025-03-20
- 2023-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$195.00K.
- 2023-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$196.00K.
- 2023-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$196.00K.
- 2023-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$195.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2023-12-31 | -$195.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | -$196.00K 10-Q · filed 2023-11-02 |
| 2023-06-30 | -$196.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$195.00K 10-Q · filed 2023-05-04 |
| 2022-12-31 | -$199.00K 10-K · filed 2024-03-26 |
| 2022-09-30 | -$201.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$200.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$197.00K 10-Q · filed 2022-05-11 |
| 2021-12-31 | -$198.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | -$196.00K 10-Q · filed 2021-11-17 |
| 2020-12-31 | -$187.00K 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |